SAN DIEGO, May 11, 2011 /PRNewswire/ -- Valor Medical announced today that it has received CE Mark approval for NeucrylateAN for treating cerebral aneurysms.
Neucrylate AN is a liquid embolic device that is injected through a microinfusion catheter into the aneurysm. When Neucrylate AN comes in contact with the blood in the aneurysm it immediately changes from
Charles Kerber, M.D., founder and Chief Medical Officer stated, "Neucrylate AN will be another tool for treating cerebral aneurysms, especially those with wide necks and the larger aneurysms of complicated shape. During the clinical trials the time to treat patients was reduced from hours to minutes, which should increase the surgery's safety, and certainly decreased the radiation dose."
"The CE Mark approval for Neucrylate AN in Europe is a major accomplishment for Valor Medical. We look forward to beginning commercialization activities and will begin training physicians next month in Budapest, Hungary," said H. Clark Adams, Chief Executive Officer
For additional information visit Valor Medical's web site, www.valormedical.com.
SOURCE Valor Medical
Subscribe to our Free Newsletters!
Learn the basics about diabetes and how to bring it under control with turmeric, an highly ...